Tesamorelin
Also known as: Egrifta · TH9507
An FDA-approved synthetic GHRH analog originally developed to treat HIV-associated lipodystrophy. Highly effective at reducing visceral adipose tissue.
What is Tesamorelin? An FDA-approved synthetic GHRH analog originally developed to treat HIV-associated lipodystrophy. Highly effective at reducing visceral adipose tissue.
How does Tesamorelin work? Tesamorelin is a 44-amino acid synthetic GHRH analog that stabilizes GHRH against enzymatic degradation. It binds GHRH receptors on the pituitary, increasing GH and subsequently IGF-1. Its primary clinical action is lipolysis of visceral adipose tissue, with studies showing average 17% reductions in visceral fat.
Benefits of Tesamorelin: Significant reduction in visceral fat (average 17% in clinical trials); Improved metabolic markers (triglycerides, HDL); Increased IGF-1 and GH levels; Potential cognitive benefits; FDA-approved for HIV lipodystrophy; Improved body composition
Tesamorelin dosage: Clinical dose is 2mg/day.
Tesamorelin half-life: 26 minutes
Research status: FDA Approved
Source: PeptideWiki — https://www.peptide-wiki.net/peptides/tesamorelin
Mechanism of Action
Tesamorelin is a 44-amino acid synthetic GHRH analog that stabilizes GHRH against enzymatic degradation. It binds GHRH receptors on the pituitary, increasing GH and subsequently IGF-1. Its primary clinical action is lipolysis of visceral adipose tissue, with studies showing average 17% reductions in visceral fat.
Amino Acid Sequence (44 AAs)
Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
Benefits
- Significant reduction in visceral fat (average 17% in clinical trials)
- Improved metabolic markers (triglycerides, HDL)
- Increased IGF-1 and GH levels
- Potential cognitive benefits
- FDA-approved for HIV lipodystrophy
- Improved body composition
Side Effects & Risks
- Injection site reactions
- Peripheral edema
- Arthralgia
- Myalgia
- Potential glucose intolerance
- Carpal tunnel symptoms
Where to Buy Tesamorelin
1 option across 1 vendor · Sorted cheapest first · All include direct product link
From
$49.99
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C lyophilized, 4°C reconstituted
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Clinical Trials & Human Studies1 trial
Phase 3 RCT of Tesamorelin for HIV-Associated Lipodystrophy
In 816 HIV-positive patients with abdominal lipodystrophy, tesamorelin 2mg/day for 26 weeks reduced visceral adipose tissue by 13.1% vs placebo (-0.5%, p<0.001). Waist circumference decreased 2.4 cm vs 0.3 cm (p<0.001).
Primary Outcome
Visceral adipose tissue area (VAT) change
p-value
<0.001
Igf1 Change
+138 ng/mL vs -9.1 ng/mL
Placebo Vat Change
-0.5%
Waist Circumference
-2.4 cm (tesamorelin) vs -0.3 cm (placebo)
Tesamorelin Vat Change
-13.1%
Molecular Structure
- CAS Number
- 218949-48-5
- PubChem CID
- 16137828
- Molecular Weight
- 5,136 Da
- Mol. Formula
- C221H366N72O67S
- Amino Acids
- 44-AA peptide
- Wikipedia
- View article
Research Protocol
- Dose Range
- 1–2 mg
- Frequency
- Once daily subcutaneous injection
- Cycle
- 4-12 weeks
- Half-Life
- 26 minutes
- Routes
- subcutaneous injection
- Notes
- Clinical dose is 2mg/day.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
PeptideWiki Research Team
Evidence-based research data sourced from PubMed and ClinicalTrials.gov · Last updated: February 25, 2026
Frequently Asked Questions About Tesamorelin
What is Tesamorelin?▾
An FDA-approved synthetic GHRH analog originally developed to treat HIV-associated lipodystrophy. Highly effective at reducing visceral adipose tissue.
What are the benefits of Tesamorelin?▾
Significant reduction in visceral fat (average 17% in clinical trials)
What are the benefits of Tesamorelin?▾
Improved metabolic markers (triglycerides, HDL)
What are the side effects of Tesamorelin?▾
Injection site reactions
What is the recommended dosage for Tesamorelin?▾
Clinical dose is 2mg/day.
How long should a Tesamorelin cycle last?▾
4-12 weeks
More Body Composition Peptides
View all Body Composition peptides →MK-677 (Ibutamoren)
Ibutamoren
A non-peptide, orally active growth hormone secretagogue that mimics ghrelin, significantly elevating GH and IGF-1 levels. Unique in being orally bioavailable.
CJC-1295 No DAC (Mod GRF 1-29)
Modified GRF 1-29
A synthetic 29-amino acid GHRH analog with 4 amino acid substitutions that improve stability and receptor affinity compared to Sermorelin. Unlike CJC-1295 DAC, it has no Drug Affinity Complex, giving it a short 30-minute half-life that mimics the body's natural pulsatile GHRH secretion when co-administered with a GHRP.
Follistatin-344
FST-344
A naturally occurring protein that inhibits myostatin and activin, effectively removing the biological ceiling on muscle growth.
MGF (Mechano Growth Factor)
Mechano Growth Factor
A splice variant of IGF-1 released in muscle fibers in response to mechanical damage. Activates muscle satellite cells to initiate repair and hypertrophy.